Shares of LEADS BIOLABS-B (09887) opened nearly 3% higher on Monday, with the stock last trading up 2.44% at HK$63, reflecting a turnover of HK$4.586 million. The surge comes on the heels of the company's announcement on September 14, unveiling updated Phase II clinical trial data for its wholly-owned investigational drug, 维利信® (Opasutsumimab, a PD-L1/4-1BB bispecific antibody), in combination with chemotherapy for the first-line treatment of non-small cell lung cancer (NSCLC). The updated results were presented as an oral report at the 2026 World Conference on Lung Cancer (WCLC 2026).

According to the released data, the therapy has demonstrated unprecedented high response rates, with nearly identical clinical benefits observed in both PD-L1-negative (PD-L1 tumor proportion score (TPS) less than 1%) and PD-L1-positive (PD-L1 TPS at or above 1%) patients with squamous NSCLC. Meanwhile, non-squamous NSCLC patients with PD-L1 TPS at or above 1% achieved deep and durable tumor responses. As the world's first PD-L1/4-1BB bispecific antibody to enter the marketing authorization review phase, 维利信® leverages a differentiated dual mechanism of action to deliver deeper therapeutic responses and broader clinical benefits, further extending the long-tail survival advantages established by first-generation tumor immunotherapy. Currently, 维利信® is undergoing clinical studies across 14 solid tumor indications, with accumulating evidence supporting its role as a foundational therapy in pan-tumor immuno-oncology (IO) 2.0.